Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K

Molecular Cancer Therapeutics

Volumn 11, Issue 8, 2012, Pages 1789-1798

  Munck, Joanne M ^a   Batey, Michael A ^a   Zhao, Yan ^a   Jenkins, Helen ^c   Richardson, Caroline J ^b   Cano, Celine ^b   Tavecchio, Michele ^a   Barbeau, Jody ^a   Bardos, Julia ^c   Cornell, Liam ^a   Griffin, Roger J ^b   Menear, Keith ^c   Slade, Andrew ^c   Thommes, Pia ^d   Martin, Niall M B ^c   Newell, David R ^a   Smith, Graeme C M ^d   Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c KuDOS Pharmaceuticals Ltd   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 ETHYLPIPERAZIN 1 YL) N [4 (2 MORPHOLINO 4 OXO 4H CHROMEN 8 YL)DIBENZO[B,D]THIOPHEN 1 YL]ACETAMIDE; DNA DEPENDENT PROTEIN KINASE; DOXORUBICIN; ETOPOFOS; KU 0060648; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CHEMOSENSITIZATION; CLONOGENIC ASSAY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMONES; DNA-ACTIVATED PROTEIN KINASE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; MCF-7 CELLS; MICE; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; THIOPHENES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864875154     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0535     Document Type: Article

References (44)

1. Iliakis G. The role of DNA double strand breaks in ionising radiation-induced killing of eukaryotic cells. Bioessays 1991;13 641-8. (Pubitemid 21892586)
2. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, et al. Cellular determinants of sensitivity and resistance to DNA topisomerase inhibitors. Cancer Invest 1994;12:530-42. (Pubitemid 24312486)
3. Ward J. The yield of DNA double-strand breaks produced intracellularly by ionising radiation: a review. Int J Radiat Biol 1990;57:1141-50. (Pubitemid 20177786)
4. Jackson SP. Sensing and repairing DNA double strand breaks. Carcinogenesis 2002;23:687-96. (Pubitemid 34567505)
5. Kanaar R, Hoeijmakers JH, van Ghent DC. Molecular mechanisms of DNA double-strand break repair. Trends Cell Biol 1998;8:483-9. (Pubitemid 28539407)
6. Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H, et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 1998;17:5497-508. (Pubitemid 28427063)
7. Yoshida M, Hosoi Y, Miyachi H, Ishii N, Matsumoto Y, Enomoto A, et al. Roles of DNA-dependent protein kinase and ATM in cell cycle-dependent radiation sensitivity in human cells. Int J Radiat Biol 2002;78:503-12. (Pubitemid 34680782)
8. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003;23:5706-15. (Pubitemid 36951334)
9. Blunt T, Finnie NJ, Taccioli GE, Smith GC, Demengeot J, Gottlieb TM, et al. Defective DNA-dependent protein kinase activity is linked to V(D) J recombination and DNA repair defects associated with the murine scid mutation. Cell 1995;80:813-23.
10. Caldecott K, Banks G, Jeggo P. DNA-double strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II. Cancer Res 1990;50:5778-83. (Pubitemid 20331376)
11. Jeggo PA, Caldecott K, Pidsley S, Banks GR. Sensitivity of Chinese hamster ovary mutants defective in DNA repair to topoisomerase II inihibitors. Cancer Res 1989;49:7057- 63.
12. Jeggo PA. DNA breakage and repair. Adv Genet 1998;38:185-211.
13. Lees-Miller SP, Godbout R, Chan DW, Weinfeld M, Day RS, Barron GM, et al. Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science 1995;267:1183-5.
14. Tanaka T, Yamagami T, Oka Y, Nomura T, Sugiyama H. The scid mutation in mice causes defects in the repair system for both double-strand DNA breaks and DNA cross-links. Mutat Res 1993;288:277-80. (Pubitemid 23226272)
15. Veuger SJ, Curtin NJ, Richardson CJ, Smith GCM, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADPRibose) polymerase-1. Cancer Res 2003;603:6008-15. (Pubitemid 37187504)
16. Smith G, Jackson SP. The DNA-dependent protein kinase. Genes Dev 1999;13:916-34. (Pubitemid 29200976)
17. Hansen LT, Lundin C, Helleday T, Poulsen HS, Sørenson CS, Petersen LN, et al. DNA repair rate and etoposide (VP16) resistance of tumour cell subpopulations derived from a single human small cell lung cancer. Lung Cancer 2003;40:157-64. (Pubitemid 36438716)
18. Shen H, Schultz M, Kruh GD, Tew KD. Increased expression of the DNA-dependent protein kinase confers resistance to adriamycin. Biochem Biophys Acta 1998;1381:131-8. (Pubitemid 28345095)
19. Eriksson Å, Lewensohn R, Larsson R, Nilsson A. DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity. Anticancer Res 2002;22:1787-94.
20. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7. (Pubitemid 34579158)
21. Franke TF. PI3K/Akt: getting it right matters. Oncogene 2008;27:6473-88.
22. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510.
23. Izzard RA, Jackson SP, Smith GCM. Competitive and noncompetitive inhibtion of the DNA-dependent protein kinase. Cancer Res 1999;59:2581-6. (Pubitemid 29269102)
24. Rosenweig KE, Youmell MB, Palayoor ST, Price BR. Radiosensitization of human tumour cells by the phosphatidyl inositol 3-kinase inhibitors wortmanin and LY294002 correlates with inhibition of DNA-depepndent protein kinase and prolonged G2-M delay. Clin Cancer Res 1997;3:1149-56. (Pubitemid 27319761)
25. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of luekaemia. Blood 2004:4659-65. (Pubitemid 38745999)
26. Hardcastle IR, Cockroft X, Desage El-Murr M, Leahy JJ, Stockley M, Golding BT, et al. Discovery of potent chromen-4- one inhibitors of the DNA-dependent protein kinase (DNA-PK) ising a small-molecule library approach. J Med Chem 2005;48:7829-46. (Pubitemid 41698821)
27. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RG, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase (DNA-PK) inhibitor, NU7441. Cancer Res 2006;66:5354-62. (Pubitemid 43844961)
28. Leahy JJ, Golding BT, Grif fin RJ, Hardcastle IR, Richardson C, Rigoreau L, et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg med Chem Lett 2004;14:6083-7. (Pubitemid 39531277)
29. Shinichi Y, Koshimizu I, Yoshimi H, Matsuno T, Watanabe T, Tsuchida Y, et al.inventor; Zenyaku Kogyo Kabushiki Kaisha, assignee. Treatment of prostate cancer, melanoma or hepatic cancer. United States patent US 20070244110A1. 2007 Oct 18.
30. Tsuchida R, Yamada T, Takagi M, Shimada A, Ishioka C, Katsuki Y, et al. Detection of ATM gene mutation in human glioma cell line MO59J by a rapid frameshift/stop codon assay in yeast. Radiat Res 2002;158:195-201. (Pubitemid 34851815)
31. Chen BP, Chan DW, Kobayashi J, Burma S, Asaithamby A, Morotomi- Yano K, et al. Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J Biol Chem 2005;280:14709-15. (Pubitemid 40562818)
32. Guillard S, Clarke PA, Te Peele R, Mohri Z, Bjerke L, Valenti M, et al. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 2009;8:443-53.
33. Skehan P, Storeng R, Scuderio D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxciticy assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12. (Pubitemid 20213250)
34. Griffin RJ, Fontana G, Golding BT, Guiard S, Hardcastle IR, Leahy JJ, et al. Selective benzopyranone and pyrimido[2,1- a ]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumour cell line in vitro. J Med Chem 2005;48:569-85. (Pubitemid 40139799)
35. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, et al. Antitumour activity of ZSTK474, a new phosphatidylinositol 3 - kinase inhibitor. J Natl Cancer Inst 2006;98:545-55.
36. Kong D, Yamori T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci 2007;98:1638-42. (Pubitemid 47308463)
37. Nicholson KM, Anderson NG. The protein Kinase B/AKT signalling pathway in human malignancy. Cell Signal 2002;14:381-95. (Pubitemid 34214843)
38. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, et al. Speci fi c apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 ampli fi ed and PI3KCA mutant breast cancer cells. Proc Natl Acad Sci USA 2009;106:22299-304.
39. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 30 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010;16:3670-83.
40. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (catalog of somatic mutations in cancer) database and website. Br J Cancer 2004;91:355-8. (Pubitemid 39037083)
41. Concun N, Zeillinger C, Tong D, Stimpfl M, Konig M, Printz D, et al. Comparison of p53 mutational status and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat 2003;79:37-46. (Pubitemid 36561041)
42. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-9.
43. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteller R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8. (Pubitemid 20001591)
44. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990;87:7555-9. (Pubitemid 20341755)